“Our findings show that cross-reactive, weakly neutralizing dengue antibodies are recalled in response to Zika infection, particularly during early infection,” study co-authors Dennis R. Burton, PhD, and Laura M. Walker, PhD, both of the Scripps Institute, said in an email to Contagion®
. Dr. Burton heads up his own lab at Scripps, which has been the research site
for a number of important Zika-related studies since the beginning of 2016. He is also the James & Jessie Minor Chair in Immunology at Scripps. Dr. Walker is Associate Director, Adimab, LLC in Boston.
In addition, because cross-reactive responses were “poorly neutralizing” and associated with enhanced Zika infection in vitro, the authors believe that their findings illustrate that preexisting immunity to dengue virus could “negatively affect protective antibody responses” to Zika.
“These antibodies do not prevent the elicitation of potently neutralizing Zika-specific antibodies during convalescence,” Drs. Burton and Walker added. “So, the first antibodies after Zika infection in dengue-experienced donors are poor and may even be detrimental, but if one waits, then eventually effective anti-Zika antibodies emerge.”
What are the implications of these findings for ongoing Zika vaccine development? The Scripps/Ragon team believe their results suggest that those involved in vaccine trials may need to effectively go back to the drawing board. In their email to Contagion®
, the authors noted, “Our findings suggest that vaccines should be designed to preferentially induce antibodies that bind to Zika-specific epitopes and to minimize the induction of the cross-reactive antibodies. [We] do not believe current vaccines are so designed and so we are arguing for a rethink.”
Brian P. Dunleavy is a medical writer and editor based in New York. His work has appeared in numerous healthcare-related publications. He is the former editor of Infectious Disease Special Edition.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.